SIGLEC10 and cancer: Although highly abundance of MDSCs (including gMDSC and mMDSC) were found in TME, but macrophage-targeting strategies show better therapeutic efficacy than MDSCs.24 Therefore, using SIRPα-Fc to block CD47 or Siglec10-Fc to block CD24 in macrophage-dominated MC38 and 4T1 tumors or TIGIT-Fc to block CD155 in CD8+ T-cell-dominated CT26 tumors may be a rational strategy for cancer immunotherapy.